Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: A randomized clinical trial

American Journal of Medicine

Volumn 103, Issue 3, 1997, Pages 217-222

  Rosman, Alan S ^a   Basu, Prithwijit ^a   Galvin, Kathryn ^a   Lieber, Charles S ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE;

ADULT; ALCOHOLISM; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRINKING BEHAVIOR; DRUG EFFICACY; HEMODIALYSIS; HEPATITIS B; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEROCONVERSION; VACCINATION;

ALCOHOLISM; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 0030845807     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00132-0     Document Type: Article

References (52)

1. Chopra S, Tupper JC, Ahn CS, et al. Hepatitis B markers in an alcohol treatment unit. Abstract. Gastroenterology. 79:1980;1010.
2. Basile A, Vitale G, Macor C, Scudeller G. Hepatitis B virus infection in alcoholic cirrhosis. BMJ. 282:1981;1705-1706.
3. Goudeau A, Maupas P, Dubois F, et al. Hepatitis B infection in alcoholic liver disease and primary hepatocellular carcinoma in France. Prog Med Virol. 27:1981;26-34.
4. Boron P, Sokolewicz-Bobrowska E, Boron-Kaczmarska A, et al. Antigenemia HBs and other serological markers of hepatitis B virus infection in patients with acute and chronic alcoholism. Alcohol Alcohol. 21:1986;281-283.
5. Jacobson JM, Worner TM, Sacks HS, Lieber CS. Human immunodeficiency virus and hepatitis B virus infections in a New York City alcoholic population. J Stud Alcohol. 53:1992;76-79.
6. Laskus T, Radkowski M, Lupa E, et al. Prevalence of markers of hepatitis viruses in out-patient alcoholics. J Hepatol. 15:1992;174-178.
7. Verbaan H, Andersson K, Eriksson S. Intravenous drug abuse - the major route of hepatitis C virus transmission among alcohol-dependent individuals? Scand J Gastroenterol. 28:1993;714-718.
8. Bloom BS, Hillman AL, Fendrick AM, Schwartz JS. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis. Ann Intern Med. 118:1993;298-306.
9. Degos F, Duhamel G, Brechot C. Hepatitis B vaccination in chronic alcoholics. J Hepatol. 2:1986;402-409.
10. Mendenhall C, Roselle GA, Lybecker LA, et al. Hepatitis B vaccination. Response of alcoholic with and without liver injury. Dig Dis Sci. 33:1988;263-269.
11. Maruyama N, Sata M, Ishii K, et al. Hepatitis B vaccination in alcoholics. Kansenshogaku Zasshi. 63:1989;27-34.
12. Villanueva C, Enriquez J, Just J, et al. Vaccination against the hepatitis B virus in alcoholics. Med Clin (Barc). 96:1991;211-214.
13. Nalpas B, Thepot V, Driss F, et al. Secondary immune response to hepatitis B virus vaccine in alcoholics. Alcohol Clin Exp Res. 17:1993;295-298.
14. Clemente-Ricote G, Perez-Roldan F, Banares-Canizares R, et al. The response to hepatitis B vaccine prior to orthotopic liver transplantation. Rev Esp Enferm Dig. 87:1995;516-520.
15. Stevens CE, Szmuness W, Goodman AI. Hepatitis B vaccine: immune responses in haemodialysis patients. Lancet. 2:1980;1211-1213.
16. Benhamou E, Courouce AM, Jungers P, et al. Hepatitis B vaccine: randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol. 21:1984;143-147.
17. Seaworth B, Drucker J, Starling J. Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis. 157:1988;332-337.
18. Bruguera M, Cremades M, Rodicio JL, et al. Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med. 87:(suppl 3A):1989;30S-32S.
19. Physicians' Desk Reference. 1997;Medical Economics Co, Oradell, New Jersey.
20. Blackburn GL, Bistrian BR, Maini BS, et al. Nutritional and metabolic assessment of the hospitalized patient. J Parenter Enteral Nutr. 1:1977;11-22.
21. Jilg W, Schmidt M, Deinhardt F, Zachoval R. Hepatitis B vaccination: how long does protection last? Lancet. 2:1984;458.
22. Bergamini F, Zanetti AR, Ferroni P, et al. Immune response to hepatitis B vaccine in staff and patients in renal dialysis units. J Infect. 7:(suppl1):1983;35-40.
23. Rosman AS, Basu P, Galvin K, Lieber CS. Utility of carbohydrate deficient transferrin (CDT) as a marker of relapse in alcoholic patients. Alcoholism Clin Exp Res. 19:1995;611-616.
24. Hollinger FB. Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines, and vaccine protocol recommendations. Am J Med. 87:(suppl 3A):1989;36S-40S.
25. Zar JH. Biostatistical Analysis. 2nd ed. 1984;New Jersey Prentice Hall, Englewood Cliffs.
26. Hosmer DW, Lemeshow S. Applied Logistic Regression. 1989;John Wiley & Sons, New York.
27. Machin D, Campbell MJ. Statistical Tables for the Design of Clinical Trials. 1987;79-80 Blackwell Scientific Publications, Oxford.
28. Schaffner W, Gardner P, Gross PA. Hepatitis B immunization strategies: expanding the target. Ann Intern Med. 118:1993;308-309.
29. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA. 263:1990;1218-1222.
30. Paronetto F. Immunologic reactions in alcoholic liver disease. Lieber CS. Medical and Nutritional Complications of Alcoholism: Mechanisms and Management. 1992;283-305 Plenum Publishing Co, New York.
31. Roselle GA. Alcohol and the immune system. Alcohol Health Res World. 16:1992;16-22.
32. Collier AC, Corey L, Murphy VL, Handsfield HH. Antibody to human immunodeficiency virus (HIV) and suboptimal response to hepatitis B vaccination. Ann Intern Med. 109:1988;101-105.
33. Craven DE, Awdeh ZL, Kunches LM, et al. Nonresponsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med. 105:1986;356-360.
34. Watanabe H, Matsushita S, Kamikawaji N, et al. Immune suppression gene on HLA-Bw54-DR4-DRw53 haplotype controls nonresponsiveness in humans to hepatitis B surface antigen via CD8+ suppressor T cells. Hum Immunol. 22:1988;9-17.
35. Weissman JY, Tsuchiyose MM, Tong MJ. Lack of response to recombinant hepatitis B vaccine in nonresponders to the plasma vaccine. JAMA. 260:1988;1734-1738.
36. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. NEJM. 321:1989;708-712.
37. Marescot MR, Budkowska A, Pillot J, Debre P. HLA linked immune response to S and pre-S2 gene products in hepatitis B vaccination. Tissue Antigens. 33:1989;495-500.
38. Munoz SJ. Long-term management of the liver transplant recipient. Med Clin North Am. 80:1996;1103-1120.
39. Van Thiel DH, Gavaler JS. Response to HBV vaccination in patients with severe liver disease. Absence of an HLA effect. Dig Dis Sci. 37:1992;1447-1451.
40. Andre FE, Safary A. Clinical experience with a yeast-derived hepatitis B vaccine. Zuckerman AJ. Viral Hepatitis and Liver Disease. 1988;1025-1030 lan R. Liss, Inc, New York.
41. Recombinant hepatitis B vaccine. Med Lett Drugs Ther. 28:1986;118-119.
42. Yasumura S, Shimizu Y, Yasuyama T, et al. Intradermal hepatitis B virus vaccination for low- or non-responded health-care workers. Acta Med Okayama. 45:1991;457-459.
43. Nagafuchi S, Kashiwagi S, Okada K, et al. Reversal of nonresponders and postexposure prophylaxis by intradermal hepatitis B vaccination in Japanese medical personnel. JAMA. 265:1991;2679-2683.
44. Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis B vaccine in hemodialysis patients previously nonresponsive to intramuscular hepatitis B vaccine. J Am Soc Nephrol. 5:1995;1930-1934.
45. Donati D, Gastaldi L. Controlled trial of thymopentin in hemodialysis patients who fail to respond to hepatitis B vaccination. Nephron. 50:1988;133-136.
46. Pagani S, Cruciani L, Chianelli M. Thymopentin administration and increase of sero-conversion after B-hepatitis vaccine in diabetic patients. Diabetes Res. 12:1989;199-201.
47. Meuer SC, Dumann H, Meyer-zum-Buschenfelde KH, Kohler H. Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet. 1:1989;15-18.
48. Goldwater PN. Randomized comparative trial of interferon-alpha versus placebo in hepatitis B vaccine non-responders and hyporesponders. Vaccine. 12:1994;410-414.
49. Jungers P, Chauveau P, Courouce AM, et al. Immunogenicity of the recombinant GenHevac B Pasteur vaccine against hepatitis B in chronic uremic patients. J Infect Dis. 169:1994;399-402.
50. Suzuki H, Iino S, Shiraki K, et al. Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing. Vaccine. 12:1994;1090-1096.
51. Mulley AG, Silverstein MD, Dienstag JL. Indications for use of hepatitis B vaccine, based on cost-effectiveness analysis. NEJM. 307:1982;644-652.
52. Nalpas B, Feitelson M, Brechot C, Rubin E. Alcohol, hepatotropic viruses, and hepatocellular carcinoma. Alcohol Clin Exp Res. 19:1995;1089-1095.